Inventories (Tables)

3 Months Ended

Mar. 31, 2025

Inventory Disclosure [Abstract]

Schedule of Inventory, Current

At March 31, 2025 and December 31, 2024, the Company's net inventories consisted of the following:

	March 31, 2025		December 31, 2024
Raw materials and work in process	$	10,832,574	$	11,982,045
Consigned inventory	195,976		126,090
Finished goods	3,009,545		2,897,359
Total inventories	14,038,095		15,005,494
less non-current inventories	(9,939,236)		(11,005,499)
Total inventories classified as current	$	4,098,859	$	3,999,995

Schedule of Inventory, Noncurrent

At March 31, 2025 and December 31, 2024, the Company's non-current inventories consisted of the following:

	March 31, 2025		December 31, 2024
Vibativ Raw Materials	$	5,356,857	$	6,180,347
Kristalose Raw Materials	2,421,705		2,672,720
Vaprisol Raw Materials	1,172,849		1,172,849
Sancuso Raw Materials	384,906		458,684
Caldolor Raw Materials	13,970		—
Acetadote Raw Materials	27,106		23,915
Ifetroban Raw Materials	150,403		166,923
Vibativ Finished Goods	163,688		183,057
Caldolor Finished Goods	178,130		77,382
Omeclamox	69,622		69,622
Total inventories classified as non-current	$	9,939,236	$	11,005,499